Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms

Blood

Volumn 123, Issue 17, 2014, Pages 2744-2745

  Lundberg, Pontus ^a   Nienhold, Ronny ^a   Ambrosetti, Achille ^b   Cervantes, Francisco ^c   Pérez Encinas, Manuel M ^d   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF VERONA   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2;

AUTOSOMAL DOMINANT INHERITANCE; BLOOD CELL COUNT; DISEASE PREDISPOSITION; FAMILY; GERMLINE MUTATION; HEMATOPOIESIS; LETTER; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PEDIGREE; PENETRANCE; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SOMATIC MUTATION; THROMBOCYTHEMIA; THROMBOCYTOSIS; EXON; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MUTATION; MYELOPROLIFERATIVE DISORDER;

CALRETICULIN; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PEDIGREE; PHENOTYPE; THROMBOCYTOSIS;

EID: 84902097145     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-550863     Document Type: Letter

References (10)

1. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
2. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
3. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.
4. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
5. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346-352. (Pubitemid 43990648)
6. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380. (Pubitemid 44232040)
7. Pérez-Encinas M, Bello JL, Pérez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46(3):225-229. (Pubitemid 24206749)
8. Bellanné-Chantelot C, Jego P, Lionne-Huyghe P, Tulliez M, Najman A; French group on myeloproliferative disorders. The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders. Leukemia. 2008;22(2):450-451.
9. Skoda RC. Hereditary myeloproliferative disorders. Haematologica. 2010;95(1):6-8.
10. Jones AV, Cross NC. Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol. 2013;4(4):237-253.